证券代码：600222 证券简称：太龙药业 公告编号：临 2025-047 河南太龙药业股份有限公司 关于接受间接控股股东担保并支付担保费暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为提高河南太龙药业股份有限公司（以下简称"公司"）融资 效率，公司间接控股股东郑州高新投资控股集团有限公司（以下简称 "高新投控"）拟为公司在金融机构的贷款提供最高时点金额不超过 6.97 亿元（含）的连带责任保证，担保期限自本次董事会审议通过 之日起至 2028 年 3 月 30 日止，担保费用总金额预计不超过 1,385.92 万元。 高新投控为公司间接控股股东，根据《上海证券交易所股票上 市规则》第 6.3.3 条的规定，高新投控为公司的关联法人，本次交易 构成关联交易。 本次关联交易不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。 至本次关联交易为止，过去 12 个月内，公司及公司控股子公 司与同一关联人发生的关联交易见公告正文；公司及公司控股子公司 未与其他关联方发生同类且未履行审议、披露 ...

Core Insights - The company held a performance briefing for the first half of 2025 on September 17, where it addressed inquiries regarding the increase in gross margin for its traditional Chinese medicine (TCM) decoction pieces business [1] - Management highlighted that the fluctuation in medicinal herb prices was influenced by various external factors such as natural conditions, economic environment, and market supply-demand relationships [1] - The company reported a revenue of 762 million yuan for the first half of 2025, reflecting a year-on-year decline [1] Revenue and Financial Performance - The company achieved a revenue of 762 million yuan in the first half of 2025, which represents a year-on-year decrease [1] - Sales dispatches were affected due to the uneven progress of provincial drug standardization, despite the company's main products being selected in the national collection of traditional Chinese medicine [1] Product Development and Strategy - The company is focusing on self-initiated projects that are progressing rapidly, particularly in the development of modified new drugs with clear clinical value, high technical barriers, and good patient compliance [1] - The self-initiated projects cover various therapeutic areas including respiratory, digestive, infectious diseases, tumors, and mental health [1] Market Conditions - Management noted that the company is closely monitoring the prices of medicinal herbs due to the diverse range of herb varieties and specifications [1] - The company is leveraging the "Tongjun Hall Digital Center" to enhance the traceability system for medicinal materials [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.29% on September 10, with Tai Long Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical: closed at 21.53, up 5.08% with a trading volume of 53,100 shares and a turnover of 113 million yuan [1] - Guizhou Bai Ling: closed at 11, up 6.05% with a trading volume of 459,500 shares and a turnover of 276 million yuan [1] - Zhongsheng Pharmaceutical: closed at 20.73, up 2.27% with a trading volume of 401,500 shares and a turnover of 841 million yuan [1] - Conversely, Tai Long Pharmaceutical saw a decline of 1.36%, closing at 6.55 with a trading volume of 161,900 shares and a turnover of 106 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 225 million yuan from institutional investors, while retail investors saw a net inflow of 118 million yuan [2] - Key stocks with significant capital flow included: - Guizhou Bai Ling: net inflow of 28.80 million yuan from institutional investors, but a net outflow of 28.34 million yuan from retail investors [3] - Kunming Pharmaceutical: net inflow of 27.63 million yuan from institutional investors, with a net outflow of 14.18 million yuan from retail investors [3] - Zhongsheng Pharmaceutical: net inflow of 20.23 million yuan from institutional investors, but a net outflow of 55.71 million yuan from retail investors [3]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Core Viewpoint - The company has received approval to register and issue a total of up to 800 million RMB in short-term financing bonds, which will be managed by two banks as joint lead underwriters [1][2]. Group 1 - The company held board meetings on July 1 and July 17, 2025, to approve the application for the issuance of short-term financing bonds [1]. - The registration amount for the short-term financing bonds is set at 800 million RMB, valid for two years from the date of the acceptance notice [1][2]. - The company plans to issue the bonds in phases during the registration validity period, depending on its funding needs and market conditions [2]. Group 2 - The company is required to disclose the issuance results through channels recognized by the trading association after the completion of the bond issuance [2]. - The issuance will comply with relevant laws, regulations, and self-regulatory management rules set by the trading association [2].

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-046 河南太龙药业股份有限公司 关于超短期融资券获准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）分别于 2025 年 7 月 1 日、2025 年 7 月 17 日召开第九届董事会第三十二次会议和 2025 年第二次临时股东大会，审议通过了《关于拟申请注册发行超 短期融资券的议案》，同意公司向中国银行间市场交易商协会（以下 简称"交易商协会"）申请注册发行总额不超过（含）人民币 8 亿元 的超短期融资券。具体内容详见公司于 2025 年 7 月 2 日、2025 年 7 月 18 日在上海证券交易所网站（www.sse.com.cn）披露的相关公告。 近日，公司收到中国银行间市场交易商协会出具的《接受注册通 知书》（中市协注﹝2025﹞SCP239 号），交易商协会决定接受公司 科技创新债券注册，主要内容如下： 二、公司在注册有效期内可分期发行，接受注册后如需备案发行， 应事前先向交易商协会备案。公 ...

Core Viewpoint - Tailong Pharmaceutical (600222.SH) has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, indicating a strategic move to raise funds through short-term financing [1] Group 1: Registration Details - The company has registered for a super short-term financing bond with a total amount of 800 million yuan [1] - The registration is valid for two years from the date of the notice and is underwritten by China Minsheng Banking Corp and Shanghai Pudong Development Bank [1] - The company can issue the bonds in installments during the registration period and must file with the association prior to any issuance [1]

Core Viewpoint - Tailong Pharmaceutical (600222.SH) has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, indicating a strategic move to raise funds through short-term financing [1] Group 1: Registration Details - The company has registered a super short-term financing bond with a total amount of 800 million yuan [1] - The registration is valid for two years from the date of the notice and is co-led by China Minsheng Banking Corp and Shanghai Pudong Development Bank [1] - The company can issue the bonds in installments during the registration period and must file with the association prior to any issuance [1]

Core Viewpoint - TaiLong Pharmaceutical (600222.SH) has received a registration notice from the National Association of Financial Market Institutional Investors for its technology innovation bonds, indicating a strategic move to raise funds through short-term financing [1] Group 1: Company Actions - The company has registered a total amount of 800 million yuan for its ultra-short-term financing bonds [1] - The registration validity period is set for two years from the date of the notice [1] - The joint lead underwriters for this bond issuance are China Minsheng Bank and Shanghai Pudong Development Bank [1]

Core Viewpoint - Tailong Pharmaceutical (600222.SH) has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, indicating a strategic move to raise funds through short-term financing [1] Group 1: Company Announcement - The company announced the acceptance of its registration for technology innovation bonds, specifically ultra-short-term financing bills [1] - The registered amount for the bonds is set at 800 million yuan, with the registration validity period being two years from the date of the notice [1] - China Minsheng Banking Corp. and Shanghai Pudong Development Bank are appointed as the joint lead underwriters for this bond issuance [1]